Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Kempharm Inc (KMPH)

Kempharm Inc (KMPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 25,716
  • Shares Outstanding, K 4,315
  • Annual Sales, $ 12,840 K
  • Annual Income, $ -24,520 K
  • 60-Month Beta 3.10
  • Price/Sales 1.63
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade KMPH with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.07 +17.44%
on 01/08/21
19.52 -69.47%
on 12/21/20
-8.76 (-59.51%)
since 12/15/20
3-Month
5.07 +17.44%
on 01/08/21
22.08 -73.01%
on 11/24/20
-4.44 (-42.70%)
since 10/15/20
52-Week
1.94 +207.85%
on 05/21/20
22.08 -73.01%
on 11/24/20
-1.72 (-22.40%)
since 01/15/20

Most Recent Stories

More News
KemPharm's KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the 2021 APSARD Virtual Conference

Combination of Oral and Poster Presentations Scheduled for January 15, 2021

KMPH : 5.96 (-2.61%)
KemPharm Participating in BIO @ JPM and Fierce JPM Week 2021 Virtual Events During "J.P. Morgan Week 2021"

KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the company is participating in BIO @ JPM and Fierce...

JPM : 138.64 (-1.79%)
KMPH : 5.96 (-2.61%)
KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market

Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol "KMPH" today, January 8, 2021

KMPH : 5.96 (-2.61%)
KemPharm Announces 1-for-16 Reverse Stock Split

KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company's Board of Directors has approved a 1-for-16...

KMPH : 5.96 (-2.61%)
KemPharm Files IND for KP879 for the Treatment of Stimulant Use Disorder

KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced it has filed an Investigational New Drug (IND) application...

KMPH : 5.96 (-2.61%)
Pain Relief Therapeutics Market Share 2020 : Growth Opportunities with Covid-19 Impact Analysis, Business Structure with Top Key Players Size, Development Plans and Challenges Forecast to 2026

The rising prevalence of chronic diseases such as a variety of cancers, osteoarthritis, stomach ulcer, chronic arthritis and diabetes are major key factor which drives the Global Pain Relief Therapeutics...

ABT : 111.30 (+1.15%)
ACRX : 2.08 (+11.83%)
ACOR : 6.70 (+5.18%)
AXSM : 76.75 (-3.93%)
BAYRY : 15.8200 (-1.37%)
BDRFF : 117.1500 (+2.76%)
BDSI : 4.31 (-0.92%)
BMY : 66.54 (+0.79%)
COLL : 24.06 (+7.94%)
DEPO : 7.30 (+1.67%)
DRRX : 2.03 (-3.79%)
EGLT : 0.0315 (-63.37%)
LLY : 190.77 (+2.19%)
FLXN : 13.06 (-0.23%)
GLPG : 100.01 (-1.68%)
HRTX : 17.64 (-3.82%)
KMPH : 5.96 (-2.61%)
MRK : 83.38 (+1.47%)
MESO : 9.72 (-1.12%)
NKTR : 16.98 (-4.61%)
NVS : 95.63 (+1.07%)
ORXOY : 5.8300 (+7.96%)
PFE : 36.70 (-0.14%)
REGN : 517.93 (unch)
SRNE : 9.50 (+18.90%)
VRX.TO : 30.80 (-3.33%)
KemPharm Participates in KP415 Late-Cycle Communication Meeting with FDA

KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company participated in a late-cycle communication...

KMPH : 5.96 (-2.61%)
REMINDER: KemPharm and Corium to Co-Host "KP415 Market Opportunity and Commercialization Strategy" Investor Event

Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET

KMPH : 5.96 (-2.61%)
KemPharm Provides Update on Development Pipeline

IND for KP879 Expected to be Filed Before Year-End 2020; New Prodrug Candidate Added to Pipeline, Targeting Rare CNS Disease, Idiopathic Hypersomnia (IH)

KMPH : 5.96 (-2.61%)
KemPharm and Corium to Co-Host "KP415 Market Opportunity and Commercialization Strategy" Investor Event

Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET

KMPH : 5.96 (-2.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar